educational program to decrease benzo use in elderly

one of the "choosing wisely" items of the american geriatric society is to avoid the use of benzodiazepines in people over 65 yo because of the associated increased risk of falls and hip fractures. of note, benzos comprise 20-25% of "inappropriate" scripts for elderly, with prevalence of use at 5-32% in community-dwelling elders. a study was done of direct-to-consumer advertising to see if that could decrease benzo usage in community-dwelling people >65yo on chronic benzos (see benzo education in elderly jama intmed 2014 in dropbox, or  doi:10.1001/jamainternmed.2014.949). in this study community pharmacies were randomly assigned to either intervention or control, with approx 150 patients aged 65-95 yo in each group. patients in the active arm of the trial got an 8-page booklet with a self-assessment component about benzo use, presentation of evidence of benzo harm, drug interactions, peer champion stories to augment self-efficacy, suggestions for alternative therapies for insomnia or anxiety, and specifics for stepwise taper. the patients were then urged to discuss this with their MD or pharmacist. they then measured benzo usage 6 months later. results:

    --indication for chronic benzos: 60% for insomnia and 48% for anxiety, mean duration 10 years and average daily dose = 1.3mg equivalents of lorazepam
    --86% of participants completed the 6-month follow-up
    --of those in the intervention group, 62% initiated conversation about benzo cessation with their medical provider and/or pharmacist
    --at 6 months, 27% in the intervention group and 5% in control group had discontinued the benzos, a highly significant difference, with NNT of 4.  dose reduction in an additional 11%
    --no interaction effect in subgroup analysis for age>80, sex, duration of use, indication for use, dose, prior attempts to taper, concomitant polypharmacy (>10 drugs/d)

so, pretty remarkable changes through direct patient education and empowerment. 27% of patients on reasonably high doses of benzos for 10 years were able to completely taper off benzos and additional 11% to cut back!! runs counter to the complacent attitude that "my patient is doing fine. stable. sleeping better. why change anything since he/she is having no problems/falls. and besides, he/she probably is addicted and will go through potentially traumatic withdrawal....."

Comments

Post a Comment

if you would like to receive the near-daily emails regularly, please email me at gmodest@uphams.org

Popular posts from this blog

cystatin c: better predictor of bad outcomes than creatinine

  another article found significant discordance between creatinine and cystatin C in assessing renal function,  finding that the latter correlated most strongly with both renal and non-renal adverse clinical outcomes (see   ckd cystatin c better than creat AJKD2023  in  dropbox or doi: 10.1053/ j.ajkd.2023.04.002)   Details: -- 158,601 adults who were in the Stockholm Creatinine Measurements (SCREAM) project and had testing of creatinine and cystatin C on the same day during a healthcare encounter, from 2010-2018     -- >400,000 outpatient tests were done for both creatinine and cystatin C levels -- mean age 62, 48% female -- mean eGFR by creatinine (   eGFR cr ) 80; mean eGFR by cystatin C ( eGFR cys  ) 73 -- mean stage of renal insufficiency: 39%  eGFR cr   90+; 38%  eGFR cr  60-89; 12%  eGFR cr  45-59; 7.1%  eGFR cr  30-44; 3.2%  eGFR cr  15-29, 0.7%  eGFR cr ...
Read more

diabetes DPP-4 inhibitors and the risk of heart failure

the FDA just came out with a safety alert about 2 DPP-4 inhibitors and the increased risk of heart failure (released 04/05/2016)(see  http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm494252.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery ​ ). details: --saxagliptin and alogliptin were singled out because of 2 clinical trials in diabetic patients with heart disease. in each trial more patients taking these meds were hospitalized for heart failure vs those on placebo     --in the saxagliptin trial: 3.5% were hospitalized for heart failure (vs 2.8% on placebo). risk factors included prior heart failure or kidney disease     --in the alogliptin trial: 3.9% were hospitalized for heart failure (vs 3.3% on placebo) --recommendation by the FDA:     -- we should consider stopping these drugs if the patient develops heart failure ...
Read more

UPDATE: ASCVD risk factor critique

I decided to do an extensive update of my prior ASCVD (atherosclerotic cardiovascular disease) risk analysis and critique of risk calculators, with much more information about the “non-traditional” risk factors. I felt that there should be more data/clarification, since I think we are really undertreating/not preventing the most common cause of death by relying on the current ASCVD risk calculators   -- Cardiovascular risk models:      -- many of us rely on the various cardiovascular risk models to determine the appropriate approach to patients, and these are often integrated into the electronic medical records      -- these risk models have several very important limitations:          -- they are typically based on community data, eg from the Framingham study etc. But, in clinical practice, we are dealing with the individual and not the community:          ...
Read more